The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure
- PMID: 17584564
- DOI: 10.1016/j.ahj.2007.04.002
The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure
Abstract
Background: N-terminal pro-brain natriuretic peptide (NT-proBNP) carries prognostic information in patients with chronic heart failure and predicts risk for mortality and cardiovascular events. It is unknown whether NT-proBNP predicts risk for hospitalization for any cause. Furthermore, a clinically useful algorithm for risk stratification based on NT-proBNP as a continuous variable has not yet been described. We therefore evaluated NT-proBNP as a risk marker for mortality and hospitalization and developed a simple algorithm for risk stratification based on NT-proBNP as a continuous variable.
Methods: Data from 345 patients with chronic heart failure were collected prospectively in our heart failure clinic, and the patients were followed for 28 months (median). Seventy patients died, and 201 patients were hospitalized. Cox proportional hazard models for mortality and hospitalization were constructed with NT-proBNP as a dichotomous (median 1381 pg/mL) and a continuous variable (log2 NT-proBNP).
Results: Patients with supramedian levels of NT-proBNP had a 2.40-fold (95% CI 1.40-4.10) increased risk for mortality and 1.71-fold (95% CI 1.24-2.36) increased risk for hospitalization. The effect of doubling NT-proBNP on adjusted hazard ratios was 1.56 (95% CI 1.32-1.85) for mortality and 1.19 (95% CI 1.09-1.31) for hospitalization. We observed a curvilinear relationship between NT-proBNP and risk for mortality and hospitalization in the whole range of NT-proBNP.
Conclusions: N-terminal pro-brain natriuretic peptide predicts risk for hospitalization and mortality. A simple algorithm indicates that every time NT-proBNP is doubled, estimated hazard ratio for death increases by a factor of 1.56 (56%) and by a factor of 1.19 (19%) for hospitalization. Finally, the relationship between NT-proBNP and risk is curvilinear if NT-proBNP is considered as a continuous variable.
Similar articles
-
N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients.Circulation. 2004 Oct 12;110(15):2168-74. doi: 10.1161/01.CIR.0000144310.04433.BE. Epub 2004 Sep 27. Circulation. 2004. PMID: 15451800
-
Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. doi: 10.1016/j.jacc.2007.08.012. Epub 2007 Oct 29. J Am Coll Cardiol. 2007. PMID: 17996563
-
Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure.J Heart Lung Transplant. 2006 Oct;25(10):1230-40. doi: 10.1016/j.healun.2006.08.004. J Heart Lung Transplant. 2006. PMID: 17045936
-
Prognostic value of brain natriuretic peptide in noncardiac surgery: a meta-analysis.Anesthesiology. 2009 Aug;111(2):311-9. doi: 10.1097/ALN.0b013e3181aaeb11. Anesthesiology. 2009. PMID: 19602961 Review.
-
Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.JACC Heart Fail. 2014 Apr;2(2):148-58. doi: 10.1016/j.jchf.2013.11.007. JACC Heart Fail. 2014. PMID: 24720923 Review.
Cited by
-
Big endothelin-1 as a clinical marker for ventricular tachyarrhythmias in patients with post-infarction left ventricular aneurysm.Anatol J Cardiol. 2019 Nov;22(5):256-261. doi: 10.14744/AnatolJCardiol.2019.67862. Anatol J Cardiol. 2019. PMID: 31674930 Free PMC article.
-
Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims.Circ Heart Fail. 2011 Sep;4(5):628-36. doi: 10.1161/CIRCHEARTFAILURE.111.962290. Epub 2011 Jul 8. Circ Heart Fail. 2011. PMID: 21743005 Free PMC article.
-
Effects of candesartan cilexetil "add-on" treatment in congestive heart failure outpatients in daily practice.Clin Res Cardiol. 2009 Jun;98(6):379-89. doi: 10.1007/s00392-009-0011-7. Epub 2009 Mar 18. Clin Res Cardiol. 2009. PMID: 19294444 Clinical Trial.
-
Excess long-term risk of adverse outcomes in heart failure patients with high and low levels of NT-proBNP: A 7-year follow-up study (NorthStar Trial).Int J Cardiol Heart Vasc. 2024 Jun 8;53:101441. doi: 10.1016/j.ijcha.2024.101441. eCollection 2024 Aug. Int J Cardiol Heart Vasc. 2024. PMID: 39228977 Free PMC article.
-
Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques (Macaca mulatta).Comp Med. 2020 Oct 1;70(5):348-357. doi: 10.30802/AALAS-CM-19-000117. Epub 2020 Aug 10. Comp Med. 2020. PMID: 32778203 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials